Stay updated with breaking news from Mark Lappe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Inhibrx, Inc. (NASDAQ:INBX – Get Rating) was down 5.1% during mid-day trading on Thursday . The company traded as low as $18.53 and last traded at $18.56. Approximately 89,389 shares were traded during trading, a decline of 78% from the average daily volume of 402,419 shares. The stock had previously closed at $19.56. Wall Street […]
Should You Buy or Sell Inhibrx Stock? Get The Latest INBX Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Inhibrx has received the orphan drug designation from the European Commission (EC) for its INBRX-109 to treat chondrosarcoma.
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...
SAN DIEGO, Aug. 15, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a st...